Cargando…
Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide
SIMPLE SUMMARY: Given the significant costs and lengthy timelines of drug development and clinical trials, drug repositioning is a promising alternative to find effective treatments for brain tumors quickly and inexpensively. In the present study, using a simple drug screen of macrolides, we found t...
Autores principales: | Eda, Takeyoshi, Okada, Masayasu, Ogura, Ryosuke, Tsukamoto, Yoshihiro, Kanemaru, Yu, Watanabe, Jun, On, Jotaro, Aoki, Hiroshi, Oishi, Makoto, Takei, Nobuyuki, Fujii, Yukihiko, Natsumeda, Manabu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833675/ https://www.ncbi.nlm.nih.gov/pubmed/35159037 http://dx.doi.org/10.3390/cancers14030770 |
Ejemplares similares
-
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018) -
ET-6 EFFICACY OF NEAR-INFRARED PHOTOIMMUNOTHERAPY TARGETING PODOPLANIN IN MALIGNANT GLIOMAS
por: Natsumeda, Manabu, et al.
Publicado: (2022) -
ACT-05 Present and future of precision-based medicine using cancer genome panels
por: Natsumeda, Manabu, et al.
Publicado: (2020) -
COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA
por: Tsukamoto, Yoshihiro, et al.
Publicado: (2019) -
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)